KLC2

Across TCGA pan-cancer cohorts, KLC2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated KLC2 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher KLC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLC2 expression acts as an unfavorable survival marker.

THYM, MESO, and HNSC are the cancer types where KLC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
HNSC	OS	Median	III,IV	0.153	0.656	.014	12	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
KIRP	DFS	Median	All	0.589	0.857	.018	6	view →
SCLC	DFS	Median	III,IV	0.137	0.546	.042	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KLC2–THYM (OS)

Open the THYM breakdown →